Erlolieva 150mg Tablet: Targeted Epidermal Growth Factor Receptor (EGFR) Inhibition for Advanced Oncology Are you searching for a reliable Erlolieva 150 mg tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of targeted tyrosine kinase inhibitors. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is Erlolieva 150mg? Erlolieva 150mg is an oral targeted therapy containing the active pharmaceutical ingredient Erlotinib. Manufactured by Allieva Pharma Pvt Ltd, this 150mg tablet belongs to the class of medications known as EGFR Tyrosine Kinase Inhibitors (TKIs). It is a cornerstone treatment for patients with specific genetic mutations in non-small cell lung cancer and advanced pancreatic malignancies, designed to interrupt the molecular signals that drive cancer progression. 1. Therapeutic Indications Metastatic Non-Small Cell Lung Cancer (NSCLC): Used as first-line, maintenance, or second-line therapy for patients whose tumors have specific EGFR mutations (Exon 19 deletions or Exon 21 L858R substitution). Advanced Pancreatic Cancer: Used in combination with Gemcitabine for the treatment of patients with locally advanced, unresectable, or metastatic pancreatic cancer. Maintenance Therapy: Indicated for patients with locally advanced or metastatic NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. 2. Mechanism of Action: Reversible Receptor Blockade EGFR Targeting: It targets the Epidermal Growth Factor Receptor (EGFR), a protein on the surface of cells that normally helps them grow and divide. In many cancer cells, this receptor is overactive or mutated. ATP Competition: Erlotinib binds reversibly to the Adenosine Triphosphate (ATP) binding site of the receptor's intracellular tyrosine kinase domain. Signal Interruption: By blocking ATP, it prevents the phosphorylation process required to send growth signals to the nucleus, effectively stalling tumor cell proliferation and inducing apoptosis (programmed cell death). 3. Administration and Dosage Management Standard Dosing: The typical dose is 150 mg once daily for NSCLC and 100 mg once daily for pancreatic cancer (in combination with gemcitabine). Timing: Must be taken on an empty stomach, at least 1 hour before or 2 hours after a meal. Food significantly increases the bioavailability, which can lead to increased toxicity. Storage: Keep at room temperature, away from moisture and direct heat, in its original packaging. Clinical Side Effects & Safety Monitoring Dermatological Safety: An “acne-like“ rash is very common and often indicates the drug is working. Patients should also monitor for dry skin and nail changes. Gastrointestinal Health: Potential for diarrhea, nausea, and stomatitis. Severe diarrhea may require dose interruption or hydration therapy. Pulmonary Monitoring: Rare but serious risk of Interstitial Lung Disease (ILD). Patients should report any new or worsening cough or shortness of breath. Ocular Safety: Monitoring for corneal ulceration or perforation, especially in patients with a history of dry eyes. Drug Interactions: Avoid proton pump inhibitors (PPIs) and smoking, as both can significantly reduce the concentration of erlotinib in the blood. Why Source Erlolieva 150mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s Erlolieva with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for the USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383
Washington, USA
08048034998
+919405476170
Chat with us
Chat with us